SLC2A3 and prostate carcinoma: For example, in individuals with colorectal cancer, increased SLC2A3 expression was related with decreased overall survival and disease-free survival (Kim et al., 2019), while increased SLC16A5 expression predicted increased survival in prostate cancer patients (Meng et al., 2021).